|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Furger KA, Menon RK, Tuck AB, Bramwell VH
and Chambers AF: The functional and clinical roles of osteopontin
in cancer and metastasis. Curr Mol Med. 1:621–632. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Denhardt DT and Guo X: Osteopontin: a
protein with diverse functions. FASEB J. 7:1475–1482.
1993.PubMed/NCBI
|
|
4
|
Brown LF, Papadopoulos-Sergiou A, Berse B,
et al: Osteopontin expression and distribution in human carcinomas.
Am J Pathol. 145:610–623. 1994.PubMed/NCBI
|
|
5
|
Agrawal D, Chen T, Irby R, et al:
Osteopontin identified as lead marker of colon cancer progression,
using pooled sample expression profiling. J Natl Cancer Inst.
94:513–521. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Coppola D, Szabo M, Boulware D, et al:
Correlation of osteopontin protein expression and pathological
stage across a wide variety of tumor histologies. Clin Cancer Res.
10:184–190. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tuck AB and Chambers AF: The role of
osteopontin in breast cancer: clinical and experimental studies. J
Mammary Gland Biol Neoplasia. 6:419–429. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tuck AB, Chambers AF and Allan AL:
Osteopontin overexpression in breast cancer: knowledge gained and
possible implications for clinical management. J Cell Biochem.
102:859–868. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tuck AB, O'Malley FP, Singhal H, et al:
Osteopontin expression in a group of lymph node negative breast
cancer patients. Int J Cancer. 79:502–508. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Singhal H, Bautista DS, Tonkin KS, et al:
Elevated plasma osteopontin in metastatic breast cancer associated
with increased tumor burden and decreased survival. Clin Cancer
Res. 3:605–611. 1997.PubMed/NCBI
|
|
11
|
Bellahcène A and Castronovo V: Increased
expression of osteonectin and osteopontin, two bone matrix
proteins, in human breast cancer. Am J Pathol. 146:95–100.
1995.PubMed/NCBI
|
|
12
|
Bramwell VH, Doig GS, Tuck AB, et al:
Serial plasma osteopontin levels have prognostic value in
metastatic breast cancer. Clin Cancer Res. 12:3337–3343. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chang J, Clark GM, Allred DC, Mohsin S,
Chamness G and Elledge RM: Survival of patients with metastatic
breast carcinoma: importance of prognostic markers of the primary
tumor. Cancer. 97:545–553. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Stang A: Critical evaluation of the
Newcastle-Ottawa scale for the assessment of the quality of
nonrandomized studies in meta-analyses. Eur J Epidemiol.
25:603–605. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
de Silva Rudland S, Martin L, Roshanlall
C, et al: Association of S100A4 and osteopontin with specific
prognostic factors and survival of patients with minimally invasive
breast cancer. Clin Cancer Res. 12:1192–1200. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kim YW, Park YK, Lee J, Ko SW and Yang MH:
Expression of osteopontin and osteonectin in breast cancer. J
Korean Med Sci. 13:652–657. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Rudland PS, Platt-Higgins A, El-Tanani M,
et al: Prognostic significance of the metastasis-associated protein
osteopontin in human breast cancer. Cancer Res. 62:3417–3427.
2002.PubMed/NCBI
|
|
18
|
Pang H, Lu H, Song H, et al: Prognostic
values of osteopontin-c, E-cadherin and beta-catenin in breast
cancer. Cancer Epidemiol. 37:985–992. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang X, Chao L, Ma G, et al: Increased
expression of osteopontin in patients with triple-negative breast
cancer. Eur J Clin Invest. 38:438–446. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Stewart LA and Parmar MK: Meta-analysis of
the literature or of individual patient data: is there a
difference? Lancet. 341:418–422. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu LY, Wang M, Ma ZB, et al: The role of
adiponectin in breast cancer: a meta-analysis. PLoS One.
8:e731832013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lum DW, Perel P, Hingorani AD and Holmes
MV: CYP2D6 genotype and tamoxifen response for breast cancer: a
systematic review and meta-analysis. PLoS One. 8:e766482013.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Qu Q, Mao Y, Fei XC and Shen KW: The
impact of androgen receptor expression on breast cancer survival: a
retrospective study and meta-analysis. PLoS One. 8:e826502013.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang Z, Ni C, Chen W, et al: Expression
of CXCR4 and breast cancer prognosis: a systematic review and
meta-analysis. BMC Cancer. 14:492014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ribeiro-Silva A and Oliveira da Costa JP:
Osteopontin expression according to molecular profile of invasive
breast cancer: a clinicopathological and immunohistochemical study.
Int J Biol Markers. 23:154–160. 2008.PubMed/NCBI
|
|
26
|
Allan AL, George R, Vantyghem SA, et al:
Role of the integrin-binding protein osteopontin in lymphatic
metastasis of breast cancer. Am J Pathol. 169:233–246. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chambers AF, Groom AC and MacDonald IC:
Dissemination and growth of cancer cells in metastatic sites. Nat
Rev Cancer. 2:563–572. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tuck AB, Arsenault DM, O'Malley FP, et al:
Osteopontin induces increased invasiveness and plasminogen
activator expression of human mammary epithelial cells. Oncogene.
18:4237–4246. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Dai J, Li B, Shi J, et al: A humanized
anti-osteopontin antibody inhibits breast cancer growth and
metastasis in vivo. Cancer Immunol Immunother. 59:355–366. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tuck AB, Hota C, Wilson SM and Chambers
AF: Osteopontin-induced migration of human mammary epithelial cells
involves activation of EGF receptor and multiple signal
transduction pathways. Oncogene. 22:1198–1205. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang X, Chao L, Ma G, et al: Primary
breast carcinoma: association of mammographic calcifications with
osteopontin expression. Radiology. 254:69–78. 2010. View Article : Google Scholar : PubMed/NCBI
|
